Sunday July 22, 2018
Home India ‘Stay A...

‘Stay Alive’: The Mute Psychological Film on Depression Releases on July 25

Depression is neither seen nor heard, it is just felt with silent cries

Stay Alive
STAY Alive Film Poster

– by Naina Mishra

Chandigarh, July 25, 2017: ‘Stay Alive’, the mute psychological movie starring Shweta Sharma as the protagonist is all set to be released today. The eight-minute long mute film will highlight the traumatic effects of a depressive person. Needless to say, depression is a sensitive issue which needs an awareness.

Shweta Sharma is the lead actress in the movie Stay Alive

Shweta Sharma told Newsgram, “I am very optimistic about the response from the audience. It will connect with them psychologically. Although it is eight minutes film, every minute of it accentuates the afflictions of depression”.

The actress has done street plays for social message financed by the world bank. She has also been an active member of NGO “Aashrey”.

ALSO READ: ‘Stay Alive’ – This Heart Wrenching Silent Film on Depression Speaks Volumes! 

Newsgram is the official media partner with “STAY ALIVE” directed by Amit Chauhan Film Co. The film has also been selected for Singapore International Film Festival, Lexus short films, and Downturn Urban Arts Films Festival.

Amit Chauhan is also working on the pre production of Hindi feature film titled as “Hell Kite”.

Depression is neither seen nor heard, it is just felt with silent cries. Not just that, in the recent times, it has become more of an epidemic. This is also the main reason why Amit Chauhan chose to display depression without the use of words. Because in reality, depression cannot be described in words.

-by Naina Mishra of Newsgram. Twitter @Nainamishr94

NewsGram is a Chicago-based non-profit media organization. We depend upon support from our readers to maintain our objective reporting. Show your support by Donating to NewsGram. Donations to NewsGram are tax-exempt. 
Click here for reuse options!
Copyright 2017 NewsGram

Next Story

HIV Drug Is Not Linked to Depression: Study

A new study of a popular HIV drug could ease concerns about its link to depression

A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala.
A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala. VOA

A new study of a popular HIV drug could ease concerns about its link to depression. Researchers in Uganda found that efavirenz, once feared to lead to depression and suicide, did not cause the expected negative side effects in their patients.

Efavirenz is an affordable, once-a-day pill used around the globe to treat and prevent HIV/AIDS. It’s “the treatment of choice” in most of the world, according to Africa Health Research Institute’s Mark Siedner, “especially [in] countries that depend on global aid to treat HIV.”

But some fear that efavirenz may come with a cost.

Some studies in the United States and Europe found the drug increased patients’ risk of depression or suicide, although other studies did not.

The mixed results prompted many doctors in the United States to prescribe more expensive but potentially safer drugs.

Siedner wanted to take another look at the risk of depression, this time in an African population. From 2005 until 2015, he and a team of Ugandan and U.S. doctors tracked 694 patients who took either efavirenz or another antiretroviral medication. They regularly asked the patients whether they experienced depression or suicidal thoughts.

No difference

Their analysis, published in the Annals of Internal Medicine, showed there was no difference between the two treatments. Siedner told VOA, “In other words, efavirenz was not associated with a risk of depression. If anything, there seems to be a signal that potentially it was associated with a decreased risk. But it wasn’t a strong enough [signal] for us to say that.”

The authors also reported that of the 17 participants who died in the course of the study, not a single death was a suicide.

Siedner has two possible explanations for why their findings differed from those in Western countries. “One potential cause is that every single ethnic group in the world, of course, is different, and different in many different ways — different socially, different environmentally, and in this case they may be different genetically.” His team is looking at whether the genes that control metabolism of the drug have a role to play in this story.

HIV Aids is a deadly disease.
HIV virus is Not Linked To Depression. Flickr

A second explanation could be the effectiveness of the drug. Because efavirenz is so potent, it could be keeping people healthier than they expected, so patients are less likely to report negative emotions.

The study is important, said Anthony Fauci, who heads the National Institute of Allergy and Infectious Diseases, because it pushes back against “the initial observation of suicidal ideation and suicide and depression” as caused by efavirenz. He told VOA, “I think now what you’re seeing is that with these conflicting reports, it’s likely someone will come in [with] the proposal to do a randomized study and take a look. So the story isn’t ended with this paper.”

As more research on the safety of efavirenz is conducted, new and cheaper drugs that might replace it are on the horizon. One of them, dolutegravir, might also pose a risk, however. A study in Botswana found dolutegravir was linked to neural tube defects in embryos, meaning it might not be safe for pregnant women. As always, further research is needed to confirm whether this is a common problem or specific to the population studied in Botswana.

Also read: UNAIDS : World Is At A “Defining Moment” In A Battle Against HIV/AIDS

“I think the whole field right now is in a bit of a holding pattern,” Siedner said when asked about dolutegravir and the future of HIV medication. (VOA)